Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the vaccine safeguards at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine functions by activating the mother’s body’s defences to produce defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, precisely when they are most vulnerable to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence indicating that a two-week gap is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection can still occur even if given later in the third trimester.

• Nearly 85% protection when immunised 4 weeks before birth
• Antibodies from the mother passed through placenta safeguard newborns from day one
• Protection possible with 2-week gap before premature birth
• Vaccination in third trimester still offers significant infant protection

Strong evidence from current research

The performance of the pregnancy RSV vaccine has been demonstrated through a thorough investigation undertaken in England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that six-month period, providing robust and representative evidence of the vaccine’s practical effectiveness. The study’s findings have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across diverse populations and circumstances.

The results paint a striking picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This stark contrast highlights the vaccine’s essential role in protecting against serious illness in newborns. The drop in hospital admissions above 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.

Methodology and scope of study

The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or small subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology measured practical outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine performs when administered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Learning about RSV and the dangers

Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.

The infection triggers inflammation deep within the lungs and airways, making it extremely challenging for infected babies to feed and breathe properly. Parents frequently observe their babies fighting for breath, their chests rising whilst they attempt to draw sufficient oxygen into their weakened respiratory system. Whilst most infants recover with palliative treatment, a limited though important group succumb from RSV-related complications annually, making prevention through vaccination a essential public health priority for protecting the youngest and most vulnerable members of society.

• RSV produces inflammation in lungs, causing serious respiratory problems in infants
• Approximately half of infants contract the virus during their first few months alive
• Symptoms span from mild colds to life-threatening chest infections needing hospital treatment
• More than 20,000 UK infants require serious hospital care for RSV each year
• A small number of infants succumb to RSV related complications each year in the UK

Uptake rates and specialist advice

Since the RSV vaccine programme commenced in 2024, health officials have emphasised the significance of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the maximum immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies via the placenta.

The guidance from public health bodies stays clear: pregnant women should make a priority of getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.

Regional disparities in vaccine uptake

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have achieved greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and access to the jab. These regional differences demonstrate variations in medical facilities, communication strategies, and community involvement initiatives, though the national data demonstrates robust and reliable protection irrespective of geographical location.

• NHS trusts rolling out multiple messaging strategies to connect with pregnant women
• Regional disparities in vaccination coverage levels throughout England require targeted improvement
• Community health services modifying schemes to suit specific population needs

Practical implications and parental perspectives

The vaccine’s outstanding effectiveness translates into tangible benefits for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the introduction of this protective measure, the 80% reduction in admissions equates to thousands of infants protected against severe infection. Parents no more face the distressing scenario of watching their newborns gasping for air or struggle to eat, symptoms that characterise serious RSV disease. The vaccine has fundamentally shifted the picture of neonatal breathing health, giving expectant mothers a active means to shield their most at-risk babies during those crucial first weeks.

For families like that of Malachi, whose severe RSV infection resulted in devastating brain damage, the vaccine’s accessibility carries profound emotional significance. His mother’s promotion of the jab underscores the transformative consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such grave complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to expectant mothers during their third trimester, converting what was once an inevitable seasonal threat into a controllable health concern.